Laddar...

BRAF-directed Therapy in Metastatic Colorectal Cancer

Activating BRAF mutations occur in approximately 5–10% of metastatic colorectal cancer (mCRC) patients, mostly V600E mutation, and it is associated with distinct clinical and pathological features. To date, there are no approved treatments to target this mutation. BRAF inhibitor monotherapy has limi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer J
Huvudupphovsmän: Korphaisarn, Krittiya, Kopetz, Scott
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2016
Ämnen:
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4922502/
https://ncbi.nlm.nih.gov/pubmed/27341594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000189
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!